Cellular and molecular imaging of the diabetic pancreas

Molecular and Cellular MR Imaging

Volumn , Issue , 2007, Pages 343-368

  Medarova, Zdravka ^a   Moore, Anna ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70349211405     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (156)

1. National Diabetes Fact Sheet, American Diabetes Association, http://www.diabetes.org/diabetes-statistics/national-diabetes-fact-sheet.jsp.
2. Butler, A.E. et al., Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes, Diabetes, 52, 102, 2003.
3. Mathis, D. et al., Beta-cell death during progression to diabetes, Nature, 414, 792, 2001.
4. Weir, G.C. and Bonner-Weir, S., Five stages of evolving beta-cell dysfunction during progression to diabetes, Diabetes, 53 (Suppl 3), S16, 2004.
5. Bonner-Weir, S. and Orci, L., New perspectives on the microvasculature of the islets of Langerhans in the rat, Diabetes, 31, 883, 1982.
6. Laughlin, M., Why image the pancreatic beta cell? Curr Med Chem Immun Endoc Metab Agents, 4, 251, 2004.
7. Weir, G. et al., Islet mass and function in diabetes and transplantation, Diabetes, 39, 401, 1990.
8. McCullich, D. et al., Correlation of in vivo beta-cell function test with beta-cell mass and pancreatic insulin content in streptozocin-administered baboons, Diabetes, 40, 673, 1991.
9. Bonner-Weir, S., Anatomy of the islet of Langerhans, in The Endocrine Pancreas, Samols, E., Ed., Raven Press, Ltd., New York, 1991, p. 15.
10. Bonner-Weir, S., Regulation of pancreatic beta-cell mass in vivo, Recent Prog Horm Res, 49, 91, 1994.
11. Moore, A. and Medarova, Z., Approaches for imaging the diabetic pancreas: first results, Curr Med Chem Immun Endoc Metab Agents, 4, 315, 2004.
12. Clark, P.B. et al., Neurofunctional imaging of the pancreas utilizing the cholinergic PET radioligand [18F]4-fluorobenzyltrozamicol, Eur J Nucl Med Mol Imaging, 31, 258, 2004.
13. Fujibayashi, Y. et al., A new approach toward a pancreas-seeking zinc radiopharmaceutical. I. Accumulation of 65Zn-amino acid and aminopolycarboxylic acid complexes in pancreatic tissue slices, Eur J Nucl Med, 11, 484, 1986.
14. Shiue, C.Y. et al., Potential approaches for beta cell imaging with PET and SPECT, Curr Med Chem Immun Endoc Metab Agents, 4, 271, 2004.
15. Malaisse, W.J. et al., Pancreatic fate of 6-deoxy-6-[125I]iodo-D-glucose: in vivo experiments, Endocrine, 13, 95, 2000.
16. Malaisse, W.J. et al., Pancreatic fate of 6-deoxy-6-[125I]iodo-D-glucose: in vitro experiments, Endocrine, 13, 411, 2000.
17. Malaisse, W.J. et al., Fate of 2-deoxy-2-[18F]fluoro-D-glucose in hyperglycemic rats, Int J Mol Med, 6, 549, 2000.
18. Malaisse, W.J. et al., Fate of 2-deoxy-2-[18F]fluoro-D-glucose in control and diabetic rats, Int J Mol Med, 5, 525, 2000.
19. Malaisse, W.J. et al., Pancreatic fate of D-[3H] mannoheptulose, Cell Biochem Funct, 19, 171, 2001.
20. Ladriere, L. et al., Assessment of islet beta-cell mass in isolated rat pancreases perfused with D-[(3)H]mannoheptulose, Am J Physiol Endocrinol Metab, 281, E298, 2001.
21. Malaisse, W.J. and Ladriere, L., Assessment of B-cell mass in isolated islets exposed to D-[3H]mannoheptulose, Int J Mol Med, 7, 405, 2001.
22. Malaisse, W.J., On the track to the beta-cell, Diabetologia, 44, 393, 2001.
23. Bryan, J. and Aguilar-Bryan, L., Sulfonylurea receptors: ABC transporters that regulate ATP-sensitive K(+) channels, Biochim Biophys Acta, 1461, 285, 1999.
24. Proks, P. et al., Sulfonylurea stimulation of insulin secretion, Diabetes, 51 (Suppl 3), S368, 2002.
25. Uhde, I. et al., Identification of the potassium channel opener site on sulfonylurea receptors, J Biol Chem, 274, 28079, 1999.
26. Ladriere, L. et al., Uptake of tritiated glibenclamide by endocrine and exocrine pancreas, Endocrine, 13, 133, 2000.
27. Schmitz, A. et al., Synthesis and evaluation of fluorine-18 labeled glyburide analogs as beta-cell imaging agents, Nucl Med Biol, 31, 483, 2004.
28. Schneider, S. et al., In vitro and in vivo evaluation of novel glibenclamide derivatives as imaging agents for the non-invasive assessment of the pancreatic islet cell mass in animals and humans, Exp Clin Endocrinol Diabetes, 113, 388, 2005.
29. Wangler, B. et al., Synthesis and evaluation of (S)-2-(2-[18F]fluoroethoxy)-4-([3-methyl-1-(2-piperidin- 1-yl-phenyl)-butyl-carbamoyl]-methyl)-benzoic acid ([18F]repaglinide): a promising radioligand for quantification of pancreatic beta-cell mass with positron emission tomography (PET), Nucl Med Biol, 31, 639, 2004.
30. Wangler, B. et al., Synthesis and in vitro evaluation of (S)-2-([11C]methoxy)-4-[3-methyl-1-(2-piperidine- 1-yl-phenyl)-butyl-carbamoyl]-benzoic acid ([11C]methoxy-repaglinide): a potential beta-cell imaging agent, Bioorg Med Chem Lett, 14, 5205, 2004.
31. Alejandro, R. et al., A ganglioside antigen on the rat pancreatic B cell surface identified by monoclonal antibody R2D6, J Clin Invest, 74, 25, 1984.
32. Halban, P. et al., Altered differentiated cell surface properties of transformed (RINm5F) compared with native adult rat pancreatic B cells, Endocrinology, 123, 113, 1988.
33. Kjaer, T. et al., Interleukins increase surface ganglioside expression of pancreatic islet cells in vitro, Acta Pathol Microbiol Immunol Scand, 100, 509, 1992.
34. Asfari, M. et al., Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines, Endocrinology, 130, 167, 1992.
35. Halle, J. et al., Protection of islets of Langerhans from antibodies by microencapsulation with alginatepoly- L-lysine membranes, Transplantation, 55, 350, 1993.
36. Ladriere, L. et al., Pancreatic fate of a 125I-labelled mouse monoclonal antibody directed against pancreatic B-cell surface ganglioside(s) in control and diabetic rats, Cell Biochem Funct, 19, 107, 2001.
37. Brogren, C. et al., Production and characterization of a monoclonal islet cell surface autoantibody from the BB rat, Diabetologia, 29, 330, 1986.
38. Buschard, K. et al., Antigen expression of the pancreatic beta-cells is dependent on their functional state, as shown by a specific, BB rat monoclonal antibody IC2, Acta Pathol Microbiol Immunol Scand, 96, 342, 1988.
39. Aaen, K. et al., Dependence of antigen expression on functional state of beta-cells, Diabetes, 39, 697, 1990.
40. Moore, A. et al., Non-invasive in vivo measurement of beta-cell mass in mouse model of diabetes, Diabetes, 50, 2231, 2001.
41. Woods, M. et al., Toward the design of MR agents for imaging beta-cell function, Curr Med Chem Immun Endoc Metab Agents, 4, 349, 2004.
42. Sambanis, A. et al., Development and non-invasive monitoring of a pancreatic tissue substitute, in Imaging the Pancreatic Beta Cell, Bethesda, MD, National Institutes of Health, 2003.
43. Lu, D. et al., C-13 NMR isotopomer analysis reveals a connection between pyruvate cycling and glucose-stimulated insulin secretion (GSIS), Proc Natl Acad Sci USA, 99, 2708, 2002.
44. Zheng, Q. et al., Magnetic relaxation agents for cell labeling and imaging applications, in Imaging the Pancreatic Beta Cell, Bethesda, MD, National Institutes of Health, 2003.
45. Gimi, B. et al., NMR spiral surface microcoils: applications, Magn Res Eng, 18B, 1, 2003.
46. Hanaoka, K. et al., Design and synthesis of a novel magnetic resonance imaging contrast agent for selective sensing of zinc ion, Chem Biol, 9, 1027, 2002.
47. Zhang, S. et al., A paramagnetic CEST agent for imaging glucose by MRI, J Am Chem Soc, 125, 15288, 2003.
48. Golman, K. et al., Molecular imaging with endogenous substances, Proc Natl Acad Sci USA, 100, 10435, 2003.
49. Golman, K. et al., Molecular imaging using hyperpolarized 13C, Br J Radiol, 76, S118, 2003.
50. Gepts, W., Pathologic anatomy of the pancreas in juvenile diabetes mellitus, Diabetes, 14, 619, 1965.
51. Bottazzo, G.F. et al., In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis, N Engl J Med, 313, 353, 1985.
52. Imagawa, A. et al., Pancreatic biopsy as a procedure for detecting in situ autoimmune phenomena in type 1 diabetes: close correlation between serological markers and histological evidence of cellular autoimmunity, Diabetes, 50, 1269, 2001.
53. Bulte, J.W. and Kraitchman, D.L., Monitoring cell therapy using iron oxide MR contrast agents, Curr Pharm Biotechnol, 5, 567, 2004.
54. Schulze, E. et al., Cellular uptake and trafficking of a prototypical magnetic iron oxide label in vitro, Invest Radiol, 30, 604, 1995.
55. Moore, A. et al., Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages, J Magn Reson Imaging, 7, 1140, 1997.
56. Weissleder, R. et al., Magnetically labeled cells can be detected by MR imaging, J Magn Reson Imaging, 7, 258, 1997.
57. Schoepf, U. et al., Intracellular magnetic labeling of lymphocytes for in vivo trafficking studies, Biotechniques, 24, 642, 1998.
58. Shen, T. et al., Magnetically labeled secretin retains receptor affinity to pancreas acinar cells, Bioconj Chem, 7, 311, 1996.
59. Moore, A. et al., Measuring transferrin receptor gene expression by NMR imaging, Biochim Biophys Acta, 1402, 239, 1998.
60. Josephson, L. et al., High-efficiency intracellular magnetic labeling with novel superparamagnetic- Tat peptide conjugates, Bioconjugate Chem, 10, 186, 1999.
61. Lewin, M. et al., Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells, Nat Biotechnol, 18, 410, 2000.
62. Bulte, J.W. et al., Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells, Nat Biotechnol, 19, 1141, 2001.
63. Magnitsky, S. et al., In vivo and ex vivo MRI detection of localized and disseminated neural stem cell grafts in the mouse brain, Neuroimage, 26, 744, 2005.
64. Arai, T. et al., Dual in vivo magnetic resonance evaluation of magnetically labeled mouse embryonic stem cells and cardiac function at 1.5 t, Magn Reson Med, 55, 203, 2006.
65. de Vries, I.J. et al., Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy, Nat Biotechnol, 23, 1407, 2005.
66. Anderson, S.A. et al., Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model, Blood, 105, 420, 2005.
67. Hill, J.M. et al., Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells, Circulation, 108, 1009, 2003.
68. Kraitchman, D.L. et al., In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction, Circulation, 107, 2290, 2003.
69. Bulte, J.W. et al., Feridex-labeled mesenchymal stem cells: cellular differentiation and MR assessment in a canine myocardial infarction model, Acad Radiol, 12 (Suppl 1), S2, 2005.
70. Heyn, C. et al., In vivo magnetic resonance imaging of single cells in mouse brain with optical validation, Magn Reson Med, 55, 23, 2006.
71. Shapiro, E.M. et al., In vivo detection of single cells by MRI, Magn Reson Med, 55, 242, 2006.
72. Heyn, C. et al., Detection threshold of single SPIO-labeled cells with FIESTA, Magn Reson Med, 53, 312, 2005.
73. Anderson, S.A. et al., Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis, Ann Neurol, 55, 654, 2004.
74. Sundstrom, J.B. et al., Magnetic resonance imaging of activated proliferating rhesus macaque T cells labeled with superparamagnetic monocrystalline iron oxide nanoparticles, J Acquir Immune Defic Syndr, 35, 9, 2004.
75. Kircher, M.F. et al., In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors, Cancer Res, 63, 6838, 2003.
76. Kaldany, A. et al., Trapping of peripheral blood lymphocytes in the pancreas of patients with acuteonset insulin-dependent diabetes mellitus, Diabetes, 31, 463, 1982.
77. Signore, A. et al., 123I-Interleukin-2: biochemical characterization and in vivo use for imaging autoimmune diseases, Nucl Med Commun, 24, 305, 2003.
78. Signore, A. et al., New approach for in vivo detection of insulitis in type I diabetes: activated lymphocyte targeting with 123I-labelled interleukin 2, Eur J Endocrinol, 131, 431, 1994.
79. Signore, A. et al., A radiopharmaceutical for imaging areas of lymphocytic infiltration: 123Iinterleukin- 2. Labelling procedure and animal studies, Nucl Med Commun, 13, 713, 1992.
80. Bertera, S. et al., Body window-enabled in vivo multicolor imaging of transplanted mouse islets expressing an insulin-Timer fusion protein, Biotechniques, 35, 718, 2003.
81. Moore, A. et al., MR imaging of insulitis in autoimmune diabetes, Magn Reson Med, 47, 751, 2002.
82. Billotey, C. et al., T-cell homing to the pancreas in autoimmune mouse models of diabetes: in vivo MR imaging, Radiology, 236, 579, 2005.
83. Verdaguer, J. et al., Acceleration of spontaneous diabetes in TCRβ-transgenic nonobese diabetic mice by beta cell-cytotoxic CD8+ T-cells expressing identical endogenous TCRα chains, J Immunol, 157, 4726, 1996.
84. Verdaguer, J. et al., Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice, J Exp Med, 186, 1663, 1997.
85. DiLorenzo, T. et al., MHC class I-restricted T-cells are required for all but end stages of diabetes development and utilize a prevalent T cell receptor α chain gene rearrangement, Proc Natl Acad Sci USA, 95, 12538, 1998.
86. Trudeau, J. et al., Autoreactive T cells in peripheral blood predict development of type 1 diabetes, J Clin Invest, 111, 217, 2003.
87. Amrani, A. et al., Progression of autoimmune diabetes driven by avidity maturation of a T-cell population, Nature, 406, 739, 2000.
88. Moore, A. et al., Tracking the recruitment of diabetogenic CD8+ T cells to the pancreas in real time, Diabetes, 54, 1459, 2004.
89. Lieberman, S. et al., Identification of the b-cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes, Proc Natl Acad Sci USA, 100, 8384, 2003.
90. Wraith, D.C. et al., Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy, Cell, 59, 247, 1989.
91. Metzler, B. and Wraith, D.C., Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity, Int Immunol, 5, 1159, 1993.
92. Liu, G.Y. and Wraith, D.C., Affinity for class II MHC determines the extent to which soluble peptides tolerize autoreactive T cells in naive and primed adult mice: implications for autoimmunity, Int Immunol, 7, 1255, 1995.
93. Anderton, S.M. and Wraith, D.C., Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelin, Eur J Immunol, 28, 1251, 1998.
94. Karin, N. et al., Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production, J Exp Med, 180, 2227, 1994.
95. O’Brien, B.A. et al., Apoptosis is the mode of beta-cell death responsible for the development of IDDM in the nonobese diabetic (NOD) mouse, Diabetes, 46, 750, 1997.
96. Kurrer, M.O. et al., Beta cell apoptosis in T cell-mediated autoimmune diabetes, Proc Natl Acad Sci USA, 94, 213, 1997.
97. O’Brien, B.A. et al., Beta-cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model, J Pathol, 178, 176, 1996.
98. Bar-On, H. et al., Irreversibility of nutritionally induced NIDDM in Psammomys obesus is related to beta-cell apoptosis, Pancreas, 18, 259, 1999.
99. Donath, M.Y. et al., Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes, Diabetes, 48, 738, 1999.
100. Federici, M. et al., High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program, Diabetes, 50, 1290, 2001.
101. Shimabukuro, M. et al., Role of nitric oxide in obesity-induced beta cell disease, J Clin Invest, 100, 290, 1997.
102. Shimabukuro, M. et al., Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes, Proc Natl Acad Sci USA, 95, 2498, 1998.
103. Maedler, K. et al., Distinct effects of saturated and monounsaturated fatty acids on beta-cell turnover and function, Diabetes, 50, 69, 2001.
104. Piro, S. et al., Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress, Metabolism, 51, 1340, 2002.
105. Medarova, Z. et al., Imaging beta-cell death with a near-infrared probe, Diabetes, 54, 1780, 2005.
106. Fadok, V.A. et al., Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages, J Immunol, 148, 2207, 1992.
107. Verhoven, B. et al., Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes, J Exp Med, 182, 1597, 1995.
108. Vermes, I. et al., A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V, J Immunol Methods, 184, 39, 1995.
109. van de Wiele, C. et al., Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography, J Clin Oncol, 21, 3483, 2003.
110. Boersma, H.H. et al., Comparison between human pharmacokinetics and imaging properties of two conjugation methods for 99mTc-annexin A5, Br J Radiol, 76, 553, 2003.
111. Hofstra, L. et al., Visualisation of cell death in vivo in patients with acute myocardial infarction, Lancet, 356, 209, 2000.
112. Kown, M.H. et al., In vivo imaging of acute cardiac rejection in human patients using (99m)technetium labeled annexin V, Am J Transplant, 1, 270, 2001.
113. Petrovsky, A. et al., Near-infrared fluorescent imaging of tumor apoptosis, Cancer Res, 63, 1936, 2003.
114. Schellenberger, E.A. et al., Optical imaging of apoptosis as a biomarker of tumor response to chemotherapy, Neoplasia, 5, 187, 2003.
115. Schellenberger, E.A. et al., Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI, Mol Imaging, 1, 102, 2002.
116. Sosnovik, D.E. et al., Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magnetooptical nanoparticle, Magn Reson Med, 54, 718, 2005.
117. Zhao, M. et al., Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent, Nat Med, 7, 1241, 2001.
118. Wedam, S.B. et al., Antiangiogenic and antitumor effects of bevacizumab in inflammatory and locally advanced breast cancer patients, J Clin Oncol, 24, 769, 2006.
119. Eichhorn, M.E. et al., Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging, Cancer Biol Ther, 5, 89, 2006.
120. de Lussanet, Q.G. et al., Dynamic contrast-enhanced magnetic resonance imaging of radiation therapyinduced microcirculation changes in rectal cancer, Int J Radiat Oncol Biol Phys, 63, 1309, 2005.
121. Brauer, M., In vivo monitoring of apoptosis, Prog Neuropsychopharmacol Biol Psychiatry, 27, 323, 2003.
122. Zhao, M. et al., Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo, Br J Cancer, 73, 61, 1996.
123. Poptani, H. et al., Monitoring thymidine kinase and ganciclovir-induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging, Cancer Gene Ther, 5, 101, 1998.
124. Kauppinen, R.A., Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance imaging and proton spectroscopy, NMR Biomed, 15, 6, 2002.
125. Sweet, I.R. et al., Continuous measurement of oxygen consumption by pancreatic islets, Diabetes Technol Ther, 4, 661, 2002.
126. Sweet, I.R. et al., Glucose stimulation of cytochrome C reduction and oxygen consumption as assessment of human islet quality, Transplantation, 80, 1003, 2005.
127. Zacharovova, K. et al., In vitro assessment of pancreatic islet vitality by oxymetry, Transplant Proc, 37, 3454, 2005.
128. Moore, A. et al., In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe, Cancer Res, 64, 1821, 2004.
129. Evgenov, N.V. et al., In vivo imaging of islet transplantation, Nat Med, 12, 144, 2006.
130. Hauptman, P.J. and O’Connor, K.J., Procurement and allocation of solid organs for transplantation, N Engl J Med, 336, 422, 1997.
131. Stock, P.G. and Bluestone, J.A., Beta-cell replacement for type I diabetes, Annu Rev Med, 55, 133, 2004.
132. Bretzel, R.G. et al., Improved survival of intraportal pancreatic islet cell allografts in patients with type-1 diabetes mellitus by refined peritransplant management, J Mol Med, 77, 140, 1999.
133. Ryan, E. et al., Five-year follow-up after clinical islet transplantation, Diabetes, 54, 2060, 2005.
134. Biarnes, M. et al., Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia, Diabetes, 51, 66, 2002.
135. Davalli, A.M. et al., Vulnerability of islets in the immediate posttransplantation period: dynamic changes in structure and function, Diabetes, 45, 1161, 1996.
136. Ryan, E. et al., Successful islet transplantation: continued insulin reserve provides long-term glycemic control, Diabetes, 51, 2148, 2002.
137. Robertson, R.P., Pancreas and islet transplants for patients with diabetes: taking positions and making decisions, Endoc Pract, 5, 24, 1999.
138. Inverardi, L. et al., Islet transplantation: immunological perspectives, Curr Opin Immunol, 15, 507, 2003.
139. Ryan, E. et al., Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol, Diabetes, 50, 710, 2001.
140. Pileggi, A. et al., Factors influencing islet of Langerhans graft function and monitoring, Clin Chim Acta, 310, 3, 2001.
141. Castano, L. and Eisenbarth, G., Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat, Annu Rev Immunol, 8, 647–679, 1990.
142. Atkinson, M. and Maclaren, N., The pathogenesis of insulin-dependent diabetes mellitus, N Engl J Med, 331, 1428–1436, 1994.
143. Bhargava, R. et al., Prevalence of hepatic steatosis after islet transplantation and its relation to graft function, Diabetes, 53, 1311, 2004.
144. Eckhard, M. et al., Disseminated periportal fatty degeneration after allogeneic intraportal islet transplantation in a patient with type 1 diabetes mellitus: a case report, Transplant Proc, 36, 1111, 2004.
145. Markmann, J.F. et al., Magnetic resonance-defined periportal steatosis following intraportal islet transplantation: a functional footprint of islet graft survival? Diabetes, 52, 1591, 2003.
146. Garg, A. and Misra, A., Hepatic steatosis, insulin resistance, and adipose tissue disorders, J Clin Endocrinol Metab, 87, 3019, 2002.
147. Kaufman, D. et al., In vivo, real-time, non-invasive bioluminescent imaging of transplanted islets in a functional murine model, in Imaging the Pancreatic Beta Cell, Bethesda, MD, National Institutes of Health, 2003.
148. Powers, A. et al., Using bioluminescence to non-invasively image and assess transplanted islet mass, in Imaging the Pancreatic Beta Cell, Bethesda, MD, National Institutes of Health, 2003.
149. Lu, Y. et al., Bioluminescent monitoring of islet graft survival after transplantation, Mol Ther, 9, 428, 2004.
150. Fowler, M. et al., Assessment of pancreatic islet mass after islet transplantation using in vivo bioluminescence imaging, Transplantation, 79, 768, 2005.
151. Lu, Y. et al., Repetitive microPET imaging of implanted human islets in mice, in Imaging the Pancreatic Beta Cell, Bethesda, MD, National Institutes of Health, 2003.
152. Yaghoubi, S. et al., Human pharmacokinetic and dosimetry studies of [(18)F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression, J Nucl Med, 42, 1225, 2001.
153. Massoud, T.F. and Gambhir, S.S., Molecular imaging in living subjects: seeing fundamental biological processes in a new light, Genes Dev, 17, 545, 2003.
154. Toso, C. et al., Positron-emission tomography imaging of early events after transplantation of islets of Langerhans, Transplantation, 79, 353, 2005.
155. Evgenov, N.V. et al., In vivo imaging of immune rejection in transplanted pancreatic islets, Diabetes, 55, 2419, 2006.
156. Ricordi, C. and Strom, T., Clinical islet transplantation: advances and immunological challenges, Nat Rev Immunol, 4, 259, 2004.